Coagulation disorders in severely and critically injured patients.
Forty-five patients with multiple injuries treated at an intensive care unit were studied prospectively. The patients were divided into two groups: the severely injured (no mortality) and critically injured (56% mortality). Treatment was started within two hours from the accident in all cases. The following coagulation parameters were measured for eight days: euglobulin lysis time (ELT), thromboelastography (TEG), vecalcification time (RECA), partial thromboplastin time (PTT), factor V, factor VIII, Normotest, Thrombotest, thrombin time, fibrinogen and platelets. Severe coagulation disorders were observed in one-third of the patients 12-48 hours after trauma. The abnormalities were more pronounced in patients who had sustained very severe injuries and arrived in a state of shock. The ELT was shortened 0-6 hours after the accident and accelerated coagulation was indicated simultaneously by decreased PTT, RECA, and r-values as well as by elevated Thrombotest and factor VIII values. The factor V and fibrinogen levels were initially lowered. Low platelet values at 2-4 days, prolonged thrombin and r-times, secondary decrease of fibrinogen FV, FVIII, and low Thrombotest values suggested disseminated intravascular coagulation associated with complications, such as fat embolism and "shock lung" syndromes. General bleeding tendency with high mortality was observed in 16% of the patients.
D000328:Adult; D001772:Blood Cell Count; D001778:Blood Coagulation Disorders / Q000209:etiology*; D001780:Blood Coagulation Tests; D001792:Blood Platelets; D001803:Blood Transfusion; D001930:Brain Injuries / Q000150:complications; D005165:Factor V / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D011446:Prospective Studies; D012774:Shock, Traumatic / Q000628:therapy; D013898:Thoracic Injuries / Q000150:complications; D013916:Thrombelastography; D014947:Wounds and Injuries / Q000097:blood / Q000150:complications*
D005165:Factor V; D005169:Factor VIII; D005340:Fibrinogen